Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 proof of concept study to treat the pain associated with irritable bowel syndrome with IMC-1

Next Previous
X
Search
Trial Profile

Phase 2 proof of concept study to treat the pain associated with irritable bowel syndrome with IMC-1

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib/famciclovir (Primary)
  • Indications Pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Virios Therapeutics

    • Most Recent Events

    • 11 Nov 2021 According to a Virios Therapeutics media release, company filed IND with FDA to explore the utility of IMC-1 in treating patients diagnosed with IBS.
    • 08 Feb 2021 New trial record
    • 01 Feb 2021 According to a Virios Therapeutics, Inc media release, it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). The first step in the collaboration is focused on designing a phase 2 proof of concept study to treat the pain associated with IBS, with the longer-term goal of conducting the phase 2 study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top